CPT code 81161 represents a molecular diagnostic laboratory test that analyzes deletions and possible duplications in the dystrophin (DMD) gene. This genetic assay is clinically significant for diagnosing Duchenne and Becker muscular dystrophies and for informing genetic counseling, family planning, and eligibility for targeted therapies. Nationally, accurate billing and coverage for DMD genetic testing affect access to diagnosis and subsequent care pathways for affected individuals.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes payer coverage patterns, common billing considerations, and where available, reimbursement benchmarks and policy updates that influence test utilization.

Readers will learn what CPT code 81161 denotes, the typical laboratory and clinical contexts in which the test is performed, and how major payers approach coverage and coding for DMD deletion/duplication analysis. The report also outlines common modifiers reported with laboratory services and highlights areas where policy updates or payer-specific rules commonly affect claim adjudication. Data not available in the input are noted where applicable.